ScaleReady announces a G-Rex® Grant has been awarded to LIfT Biosciences

Core Insights - LIfT BioSciences has been awarded a $300,000 G-Rex Grant to establish clinical manufacturing for its Neutrophil only Leukocyte Infusion Therapy (N-LIfT) platform, which is set to enter clinical trials [1][2] - The G-Rex manufacturing platform is designed to enhance the efficiency and scalability of cell therapy production, with LIfT aiming to utilize it to develop Immunomodulatory Alpha Neutrophils (IMANs) that target solid tumors [2][3] - ScaleReady's G-Rex Grant Program is a $20 million initiative aimed at advancing cell and gene-modified cell therapy development, providing grants and access to a consortium of partners for support [3][6] Company Overview - LIfT BioSciences is a UK and Ireland-based biotech company focused on developing a first-in-class alpha neutrophil cell therapy that addresses treatment resistance in solid tumors [4] - The company is working on engineered CAR IMAN cell therapies in collaboration with pharmaceutical partners to target various solid tumors [5] - ScaleReady provides a G-Rex-centric manufacturing platform that supports the development and manufacturing of cell and gene-modified therapies, currently utilized by over 800 organizations [6][7] Collaborations and Technology - Wilson Wolf Manufacturing, a co-inventor of the G-Rex platform, is collaborating with LIfT to create a scalable manufacturing process for N-LIfT [2][7] - Bio-Techne Corporation is partnering with Wilson Wolf to develop tailored products for G-Rex Bioreactors, enhancing the manufacturing process [8] - CellReady LLC specializes in G-Rex-based contract development and manufacturing, supporting the commercialization of cell and gene-modified therapies [9]